Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian T Ruff

Showing results (111-120 of 193) with videos related to

Pageof 20
Sort By:
Circulation|August 25, 2023
Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral AnticoagulantsRahul Aggarwal, Christian T Ruff, Saverio Virdone, et al.
Journal of the American College of Cardiology|September 22, 2018
Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 TrialRamón Corbalán, José Carlos Nicolau, José López-Sendon, et al.
Lancet (London, England)|March 15, 2015
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trialChristian T Ruff, Robert P Giugliano, Eugene Braunwald, et al.
American Heart Journal|January 25, 2021
Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 studyJoris R de Groot, Christian T Ruff, Sabina A Murphy, et al.
Circulation|May 20, 2009
Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarctionDavid A Morrow, Stephen D Wiviott, Harvey D White, et al.
Journal of the American Heart Association|May 22, 2016
Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 TrialEri Toda Kato, Robert P Giugliano, Christian T Ruff, et al.
Nature Medicine|June 8, 2026
Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variantsNicholas A Marston, Shinwan Kany, Giorgio E M Melloni, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 28, 2021
Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48Marc P Bonaca, Elliott M Antman, Jonathan W Cunningham, et al.
American Heart Journal|March 5, 2013
Central versus local adjudication of myocardial infarction in a cardiac biomarker trialStephen W Smith, Deborah B Diercks, John T Nagurney, et al.
Circulation. Cardiovascular Quality and Outcomes|June 3, 2024
Application of the Win Ratio Method in the ENGAGE AF-TIMI 48 Trial Comparing Edoxaban With Warfarin in Patients With Atrial FibrillationBrian A Bergmark, Jeong-Gun Park, Rose A Hamershock, et al.
Pageof 20

Showing results (111-120 of 193) with videos related to

Sort By:
Pageof 20
Circulation|August 25, 2023
Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral AnticoagulantsRahul Aggarwal, Christian T Ruff, Saverio Virdone, et al.
Journal of the American College of Cardiology|September 22, 2018
Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 TrialRamón Corbalán, José Carlos Nicolau, José López-Sendon, et al.
Lancet (London, England)|March 15, 2015
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trialChristian T Ruff, Robert P Giugliano, Eugene Braunwald, et al.
American Heart Journal|January 25, 2021
Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 studyJoris R de Groot, Christian T Ruff, Sabina A Murphy, et al.
Circulation|May 20, 2009
Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarctionDavid A Morrow, Stephen D Wiviott, Harvey D White, et al.
Journal of the American Heart Association|May 22, 2016
Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 TrialEri Toda Kato, Robert P Giugliano, Christian T Ruff, et al.
Nature Medicine|June 8, 2026
Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variantsNicholas A Marston, Shinwan Kany, Giorgio E M Melloni, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 28, 2021
Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48Marc P Bonaca, Elliott M Antman, Jonathan W Cunningham, et al.
American Heart Journal|March 5, 2013
Central versus local adjudication of myocardial infarction in a cardiac biomarker trialStephen W Smith, Deborah B Diercks, John T Nagurney, et al.
Circulation. Cardiovascular Quality and Outcomes|June 3, 2024
Application of the Win Ratio Method in the ENGAGE AF-TIMI 48 Trial Comparing Edoxaban With Warfarin in Patients With Atrial FibrillationBrian A Bergmark, Jeong-Gun Park, Rose A Hamershock, et al.
Pageof 20